Novo Nordisk's (NVO) Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. ADBE
8. HUMA
9. NVDA
10. CRWV

Go back to Novo Nordisk's (NVO) Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

March 8, 2024 2:57 PM EST

Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term weight management1The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease2

PLAINSBORO, N.J.,... More